AnaBios Boosts Discovery of Safer, More Effective Medicines With License From the University of Louisville
February 14, 2023 09:00 ET
|
AnaBios
SAN DIEGO, Feb. 14, 2023 (GLOBE NEWSWIRE) -- AnaBios, a preclinical contract research organization that provides ex vivo human platforms to de-risk new drugs, today announced a technology transfer...
Genmab and Synaffix Enter into License Agreement for ADC Technology
January 04, 2022 09:00 ET
|
Genmab A/S
Media Release Synaffix to provide access to proprietary antibody-drug conjugate (ADC) technologiesGenmab secures rights for conducting research on ADCs against multiple drug targets with options for...
Clarus Therapeutics and McGill University Announce Exclusive Worldwide Licensing Agreement To Develop and Commercialize Technology To Treat Rare Conditions Associated With Coenzyme-Q10 (Ubiquinone) Deficiencies
September 16, 2021 09:05 ET
|
Clarus Therapeutics Holdings, Inc.
Agreement to accelerate development of potential treatments for rare, endocrine, metabolic, and neurological conditions associated with primary and secondary ubiquinone deficiencies which belong to...
XOMA’s Royalty Portfolio Grows with Addition of Three Royalty Assets
April 15, 2021 09:05 ET
|
XOMA Corporation
EMERYVILLE, Calif., April 15, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) today announced its portfolio of potential future milestone and royalty assets has increased with the addition...
Arbutus Biopharma, X-Chem and Proteros biostructures Enter into a Pan-Coronavirus Discovery Research and License Agreement
April 01, 2021 07:30 ET
|
Arbutus Biopharma Corporation
Collaboration formed to accelerate the discovery of novel oral inhibitors targeting the SARS-CoV-2 nsp5 main protease for the treatment of COVID-19 and potential future coronavirus outbreaks ...
Xalles Announces a License Agreement with Xped Holdings to Create a Payment Platform Across Its Subsidiaries
March 19, 2021 08:00 ET
|
Xalles Holdings Inc.
Technology Development Agreement supported by an International Patent Portfolio, Including 7 U.S. Patents, Will Enhance Xalles Operating Subsidiaries to Grow Revenues and Scale Globally WASHINGTON,...
DATA443 ACQUIRES ARCMAIL™ - LEADING DATA ARCHIVING PLATFORM
February 19, 2021 08:00 ET
|
Data443 Risk Mitigation, Inc.
Culmination of Two-Year Licensing Agreement Leads to Acquisition of Full Intellectual Property, Opening New Expansion Opportunities and Competitive Markets RESEARCH TRIANGLE PARK, NC, Feb. 19, 2021 ...
Interpace Biosciences Announces License Agreement with Rutgers University and Mass General Hospital
February 01, 2021 09:27 ET
|
Interpace Biosciences, Inc.
Parsippany, NJ, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG) announced today that it has executed a license agreement with Rutgers, The State University of New...
Midwest Energy Emissions Corp. Reaches License Agreement with Large North American Utility
January 19, 2021 08:31 ET
|
Midwest Energy Emissions Corp.
Arrangement Reached with Fourth Utility Defendant CORSICANA, TX, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Midwest Energy Emissions Corp. (OTCQB: MEEC) ("ME2C" or the “Company”), a leading environmental...
Rhizen Pharmaceuticals S.A. and Curon Biopharmaceutical Limited Announce an Exclusive Licensing Agreement to Develop and Commercialize Tenalisib, a Dual PI3K Delta and Gamma Inhibitor for Oncology in Greater China
October 12, 2020 08:00 ET
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland and Shanghai, China. October 12, 2020, Oct. 12, 2020 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S. A. (Rhizen), a Switzerland-based privately held clinical-stage...